News Releases

Alcresta Therapeutics Announces Publication of NASPGHAN Position Paper Recommending RELiZORB® in Children with Chronic Pancreatitis

Feb 23, 2021

Newton, M.A. – February, 23 2021 – Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced  publication of a position paper by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) Pancreas Committee recommending the use of RELiZORB® (immobilized lipase cartridge), a first-of-its-kind digestive enzyme cartridge designed to mimic the function of pancreatic lipase.

Alcresta Therapeutics Appoints Alan Muney, MD to Board Of Directors

Dec 07, 2020

NEWTON, MA, December 7, 2020 — Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, today announced the appointment of Alan Muney, MD to its Board of Directors. Dr. Muney is currently a senior healthcare advisor for Pritzker Private Capital, Arsenal Capital, Bain Management Consulting, and NEA Venture Capital.

Alcresta Therapeutics’ RELiZORB® (immobilized lipase) cartridge shows long-term effectiveness in enterally fed patients with cystic fibrosis

Nov 11, 2020

NEWTON, MA, November 11, 2020 — Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, today announced the publication of a 12-month observational study in Journal of Pediatric Gastroenterology & Nutrition that evaluated the effectiveness of long-term RELiZORB® (iMMOBILIZED LIPASE) Cartridge use in enterally fed patients with cystic fibrosis.

Alcresta Therapeutics Announces Appointment of Jason Weiner as Chief Commercial Officer

Jul 27, 2020

Newton, MA – July 27, 2020 – Alcresta Therapeutics Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the appointment of Jason Weiner as its Chief Commercial Officer (CCO) effective July 27, 2020.

Alcresta Therapeutics Announces Publication of Consensus Statement Supporting Access to RELiZORB®

Jun 25, 2019

Warren, N.J. – June 25, 2019 – Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the publication of a consensus statement supporting the clinical outcomes of RELiZORB® (immobilized lipase cartridge) and advocating for improved payer coverage and patient access.

Alcresta Therapeutics Announces Appointment of Daniel Orlando as Chief Executive Officer

Jun 17, 2019

Warren, N.J. – June 17, 2019 – Alcresta Therapeutics Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the appointment of Daniel Orlando as its Chief Executive Officer (CEO) and member of the Board of Directors effective June 17, 2019.

Alcresta Therapeutics Announces that RELiZORB® iMMOBILIZED LIPASE CARTRIDGE has been Issued a Permanent Medicare Billing Code (B4105) by the Centers for Medicare and Medicaid Services (CMS)

Jan 03, 2019
  • Permanent B-Code for RELiZORB takes effect January 1, 2019
  • Updated coverage and pricing indicators will expand access to many patients

WARREN, N.J. – December 27, 2018 – Alcresta Therapeutics, Inc. announced the issuance of a permanent and unique billing code by the Centers for Medicare and Medicaid Services (CMS) for RELiZORB. RELiZORB is an in-line digestive enzyme cartridge and is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.

Data from the ASSURE Study of Long-Term Use of RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE Published in Journal of Pediatric Gastroenterology and Nutrition

Aug 02, 2018

Largest Prospective Trial of Enteral Feeding in Cystic Fibrosis Shows Sustained Use of RELiZORB Can Help Hydrolyze Fatty Acids and Normalize Absorption

Alcresta Therapeutics Announces RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE has been Issued a Unique Q-Code (Q9994) by CMS

Jun 18, 2018

WARREN, N.J. – June 18, 2018 – Alcresta Therapeutics, Inc. today announced the issuance of a unique Q-code by CMS for its digestive enzyme cartridge RELiZORB. RELiZORB (iMMOBILIZED LIPASE) CARTRIDGE is an in-line digestive enzyme cartridge and is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula.  The code, Q9994, is effective July 1, 2018.  CMS has instructed Medicare Administrative Contractors to add Q9994 to the relevant code set as of that date.

Alcresta Therapeutics, Inc. Presented Results at the North American Cystic Fibrosis Conference from the ASSURE Study: An Evaluation of the Long-Term Use of RELiZORB®

Nov 06, 2017

Four additional studies with RELiZORB were presented by investigators at leading cystic fibrosis centers

Pages